

DLL3

Catalog # PVGS1830

Specification

DLL3 - Product Information

Primary Accession **Species** Human

Q9NYJ7-1

Sequence

Val311-Ala479

Purity

> 95% as determined by Bis-Tris PAGE
> > 95% as determined by HPLC

Endotoxin Level

Less than 1EU per µg by the LAL method.

Biological Activity

Immobilized DLL3 Domain (311-479), His&Avi, Human (Cat.No.: Z03951) at 1 μ g/ml (100 μ l/Well) on the plate can bind Anti-DLL3 Antibody, hFc Tag

Expression System

HEK293

Theoretical Molecular Weight

21.20 kDa

Formulation Lyophilized from a 0.22 µm filtered solution in PBS, (pH 7.4).

Reconstitution

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH < sub > 2 < /sub > 0 more than 100 $\mu g/ml$.

Storage & Stability


Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

DLL3 - Additional Information

Target Background

Delta-like ligand 3 (DLL3) is an inhibitory Notch ligand. It is highly expressed on the surface of Small cell lung cancer (SCLC) and other neuroendocrine tumors. And its expression promotes SCLC migration and invasion. DLL3 agents are evaluated in several ongoing clinical studies in SCLC and other neuroendocrine tumors.

DLL3 - Protein Information





DLL3 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- <u>Immunofluorescence</u>
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

DLL3 - Images